Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study.

O'Kelly B 1,2, Vidal L 2, McHugh T 2, et. al. Brain, Behavior, & Immunity - Health, 03 Jul 2022, 24:100485, https://doi.org/10.1016/j.bbih.2022.100485 PMID: 35814187 PMCID: PMC9250701 Abstract  Background Up to 37.7% of patients experience symptoms beyond 12 weeks after…[...]

Read More